View Our Website

Compass Therapeutics is a biopharmaceutical company focused on drugging the immune system to treat human diseases.  Using its proprietary antibody discovery and screening platforms, Compass has generated a portfolio of next generation immunomodulatory biologic drug candidates, drug combinations, and multispecifics addressing unmet medical needs in oncology, autoimmunity and other diseases. The company is privately held and completed $83M in Series A financing led by OrbiMed Advisors, F-Prime Capital, Borealis Ventures, Cowen Private Investment, Alexandria Real Estate Ventures and Thiel Capital.

To learn more, visit

Current Openings